GT Biopharma, Inc. (GTBP)
Largest Insider Buys in Sector
GTBP Stock Price History Chart
GTBP Stock Performance
About GT Biopharma, Inc.
GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I/II clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is …
Insider Activity of GT Biopharma, Inc.
Over the last 12 months, insiders at GT Biopharma, Inc. have bought $0 and sold $0 worth of GT Biopharma, Inc. stock.
On average, over the past 5 years, insiders at GT Biopharma, Inc. have bought $38,149 and sold $121,634 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 50,000 shares for transaction amount of $25,000 was made by Breen Michael Martin (Executive Chairman/Interim CEO) on 2023‑04‑11.
List of Insider Buy and Sell Transactions, GT Biopharma, Inc.
| 2023-04-11 | Executive Chairman/Interim CEO | 50,000 0.123% | $0.50 | $25,000 | -45.96% | |||
| 2023-04-06 | CFO & Secretary | 50,000 0.139% | $0.50 | $25,000 | -39.13% | |||
| 2020-12-22 | Sale | 47,978 0.0139% | $0.40 | $19,191 | -7.70% | |||
| 2020-12-22 | 1,815 0.0116% | $8.84 | $16,037 | -7.70% | ||||
| 2020-12-21 | Sale | 135,722 0.0465% | $0.32 | $43,645 | +36.34% | |||
| 2020-12-18 | Sale | 50,000 0.018% | $0.30 | $15,000 | +53.68% | |||
| 2020-12-17 | Sale | 100,000 0.0357% | $0.30 | $30,500 | +49.54% | |||
| 2020-12-16 | Sale | 50,000 0.0184% | $0.30 | $15,000 | +57.14% | |||
| 2020-12-15 | Sale | 150,000 0.0538% | $0.31 | $46,000 | +49.54% | |||
| 2020-12-14 | Sale | 146,300 0.0524% | $0.29 | $41,927 | +59.85% | |||
| 2020-12-11 | Sale | 100,000 0.0342% | $0.26 | $25,500 | +71.90% | |||
| 2020-11-16 | 3,268 0.0201% | $3.14 | $10,262 | +150.57% | ||||
| 2020-06-02 | Sale | CEO | 4.23M 0.0294% | $0.00 | $4,234 | +15.00% | ||
| 2020-05-13 | Sale | CFO | 2.27M 0.0175% | $0.00 | $2,270 | +17.50% | ||
| 2019-02-06 | Sale | director | 800,000 0.0025% | $0.00 | $800 | -68.50% | ||
| 2019-02-01 | Sale | CEO | 176,980 0.0005% | $0.00 | $177 | -69.85% | ||
| 2010-12-27 | Sale | 10 percent owner | 360,100 0.0475% | $0.13 | $47,209 | |||
| 2010-12-27 | Sale | 360,100 0.0475% | $0.13 | $47,209 | ||||
| 2010-12-23 | Sale | 10 percent owner | 339,900 0.0445% | $0.13 | $44,187 | |||
| 2010-12-23 | Sale | 339,900 0.0445% | $0.13 | $44,187 |
Insider Historical Profitability
| Breen Michael Martin | Executive Chairman/Interim CEO | 656218 29.3698% | $2.09 | 1 | 0 | <0.0001% |
| Ohri Manu | CFO & Secretary | 50000 2.2378% | $2.09 | 1 | 0 | <0.0001% |
| Wendel Bruce | 5083 0.2275% | $2.09 | 2 | 0 | +71.44% |
Institutional Investor Ownership
| Retirement Group Llc | $4.00 | <0.01 | 1 | -97.73% | -$172.00 | <0.0001 |